From:	Victoria Sung </O=CELGENE/OU=EXCHANGE ADMINISTRATIVE GROUP (FYDIBOHF23SPDLT)/CN=RECIPIENTS/CN=VSUNG>
Sent:	Tuesday, July 20, 2010 2:05 PM
To:	Elizabeth Holmes <eholmes@theranos.com>
Subject:	ACE-011 Program

Hi Elizabeth,

Hope you're doing well and enjoying your summer. All of us at Celgene are very excited about the impending shipment of Theranos readers to our clinical sites and have been enjoying working with Brian, Kapil and the others to optimize sample collection, transfer, etc.. We're looking forward to getting our first patient samples onto your cartridges!

As Lea and I mentioned during our last visit to Palo Alto, we unfortunately do not have anyone in our group with bioassay development/validation experience, so had planned to hire a consultant to help us to understand the finer points of what your team is working hard to achieve. Originally, our plan was to work with Ron Bowsher on the PD assays since he is already assisting Peter Bryan with the ACE-011 PK assay development process. However, in recent correspondences with Jodi, I understand that Theranos is uncomfortable with us sharing information with Ron because he also consults for Millipore. Is this also your impression and if so, would you be comfortable with us hiring a different consultant (presumably, any given consultant in the field may likely consult for a competing company so if you simply prefer that we do not employ a consultant, please let me know).

Additionally, I wanted to make sure that we are on the same page with regard to the actual material that we would like to share with a consultant. In addition to the assay development reports, we would like the consultant to have access to data generated from our patient samples so that we can complete the validation process. This is one of the goals of the renal clinical trial and also the reason we will be coordinating the Theranos sampling schedule to coincide with the ACM sampling schedule. I realize that the numbers may not necessarily be comparable, but we can compare trends, timelines, etc.. The work that we put into validating your technology in this exploratory study will directly influence whether we continue to implement the Theranos technology in future trials. The team will be looking to Translational Development to endorse the technology and it is my hope that we will be able to do so wholeheartedly. Having the consultant on board asap is an essential part of this process, which is why I am contacting you directly.

If you'd rather talk further over the phone, please feel free to give me a call.

Best regards,
Vicki

Victoria Sung, Ph.D.
Associate Director,
Translational Development
Celgene Corporation
1500 Owens St. Suite 600
San Francisco, CA 94158
Tel: 415-839-7046
Fax: 415-839-7011